Zevra Therapeutics (ZVRA) Return on Sales (2019 - 2026)

Zevra Therapeutics' Return on Sales history runs 8 years deep, the most recent figure standing at 0.01% for Q1 2026.

• Quarterly Return on Sales rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 3.0% YoY) and the FY2025 annual result came in at 0.01%, up 5.0% from the prior year.
• Return on Sales was 0.01% for Q1 2026 at Zevra Therapeutics, up from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.03% in Q2 2025 and bottomed at 0.18% in Q2 2022.
• A 5-year average of 0.03% and a median of 0.02% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales dropped 18 bps — and 2023, when it advanced 17 bps.
• Zevra Therapeutics' Return on Sales stood at 0.01% in 2022, then fell by 5 bps to 0.02% in 2023, then sank by 93 bps to 0.03% in 2024, then jumped by 112 bps to 0.0% in 2025, then surged by 194 bps to 0.01% in 2026.
• Business Quant data shows ZVRA's Return on Sales at 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.